ReviewAging and disease2017
Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology.
Review in Aging and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 231 citations in OpenAlex.
- Body mass index and the risk of basal cell carcinoma: evidence from Mendelian randomization analysis.PeerJ · 2023Pooled it
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer · 2025Trial
- Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- A SHort course Accelerated RadiatiON therapy (SHARON) dose-escalation trial in older adults head and neck non-melanoma skin cancer.The British journal of radiology · 2022Trial
- Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia.The Journal of clinical investigation · 2021Trial
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.The Lancet. Oncology · 2020Trial
- An individualized reconstructive algorithm for large facial defects after tumor resection in elderly patients: A retrospective case series.JPRAS open · 2026Article
- Review
- Certainties, Doubts, and Myths in the Diagnosis and Treatment of Salivary Gland Tumors of the Head and Neck.Cancers · 2026Review
- Neoplastic Foot Ulcers: A Multicentre Retrospective Study.International wound journal · 2026Article
- Dosimetric evaluation of superficial radionuclide-based high-dose-rate brachytherapy for deep keratinocyte carcinoma: A case series.Journal of contemporary brachytherapy · 2026Article
- Review
- Knowledge, attitudes and practices toward skin cancer prevention among Malaysian adults: a cross-sectional online survey.BMJ open · 2026Article
- Geriatric Psychodermatology: Current Concepts and Therapeutic Strategies.Dermatology and therapy · 2026Review
- The SMAD-Pathway Mediates HMGB1-Induced Proliferation and Metastatic Progression in Cutaneous Squamous Cell Carcinoma Cells.Annals of dermatology · 2026Article
- Article
- Skin Cancer in Residential Care Facilities: A Scoping Review of Risk, Diagnosis, Psychosocial Impact, and Management.Cureus · 2026Review
- Soft Tissue Pseudomyogenic Hemangioendothelioma in the Buttock: A Case Report.Current medical imaging · 2026Article
- Temporal trends in long-term relative survival of cutaneous verrucous carcinoma: a period analysis from a large-scale SEER-based cohort.Frontiers in medicine · 2026Article
- Vitamin D and the aging skin: insights into oxidative stress, inflammation, and barrier function.Immunity & ageing : I & A · 2025Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is a worldwide, emerging clinical need in the elderly white population, with a steady increase in incidence rates, morbidity and related medical costs. Skin cancer is a heterogeneous group of cancers comprising cutaneous melanoma and non-melanoma skin cancers (NMSC), which predominantly affect elderly patients, aged older than 65 years. Melanoma has distinct clinical presentations in the elderly patient and represents a challenging question in terms of clinical management. NMSC includes the basal cell carcinoma and cutaneous squamous cell carcinoma and presents a wide disease spectrum in the elderly population, ranging from low-risk to high-risk tumours, advanced and inoperable disease. Treatment decisions for NMSC are preferentially based on tumour characteristics, patient's chronological age and physician's preferences and operational settings. Several treatment options are available for NMSC, from surgery to non-invasive/medical therapies, but patient-based factors, such as geriatric comorbidities and patient's life expectancy, do not frequently modulate treatment goals. In melanoma, age-related variations in clinical management are significant and may frequently lead to under-treatment, limiting access to advanced surgical and medical treatments. Clinical decision-making in the care of elderly skin cancer patient should ideally implement a geriatric assessment, prioritizing patient-based factors and efficiently differentiating fit from frail cancer patients. Current clinical practice guidelines for NMSC and melanoma only partially address geriatric aspects of cancer care, such as frailty, limited life-expectancy, geriatric comorbidities and treatment compliance. We review the recent evidence on the scope and problem of skin cancer in the elderly population as well as age-related variations in its clinical management, highlighting the potential role of a geriatric approach in optimizing dermato-oncological care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.